Wyszuk. zaawans.

Tom 6, Nr 1 (2021)
Praca badawcza (oryginalna)
Opublikowany online: 2021-02-09

dostęp otwarty

Pokaż PDF (angielski) Pobierz plik PDF
Wyświetlenia strony 539
Wyświetlenia/pobrania artykułu 199
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Expression of matrix metalloproteinases (MMPs) and their inhibitor (TIMP) genes on mRNA and protein levels in oral squamous cell carcinoma

Artur Wróbel-Roztropiński1, Bogna Zielińska-Kaźmierska1, Hubert Roztropiński2, Weronika Lucas-Grzelczyk3, Janusz Szemraj4, Magdalena Józefowicz-Korczyńska3
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2021;6(1):1-8.

Streszczenie

Introduction. To investigate the mRNA and protein expression of MMP-2, MMP-9, MMP-7 and their tissue inhibitor TIMP-2 in tissue specimens with oral squamous cell cancer (OSCC) and in healthy tissues.

Material and methods. The expression genes of MMP-2, MMP-9, MMP-7 and TIMP-2 on mRNA levels were detected by the RT-PCR method in 31 samples with oral squamous cell carcinoma and in 31 healthy, control tissues. Secondly, the concentration of the analysed metalloproteinases and their inhibitor was assessed in tumor and non-tumor tissues using the enzyme-linked immunosorbent assay (ELISA) method.

Results. The mean values of gene expression of MMP-2, MMP-7, MMP-9 and TIMP in tissues with oral squamous cell cancer were significantly higher in comparison to normal ones (p < 0.0001). Similar observations were found for concentration levels of analysed MMPs and TIMP in tissues with and without oral cancer (p < 0.0001).

Conclusions. The present study demonstrated that MMP-2, MMP-7, MMP-9 and TIMP-2 gene expression on protein and mRNA levels is higher in oral squamous cell carcinoma tissues than in healthy control tissues. This may suggest that MMPs and TIMP play an important role in tumorogenesis. We did not observe any correlation between the clinicopathological characteristics of patients with OSCC and expression levels of MMPs and TIMP.

Słowa kluczowe: ELISAenzyme assaysoral cancermetalloprteinases

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF

Referencje

  1. http://www.who.int/oral_health/publications/cancer_maps/en/ (10.02.2018).
  2. http://onkologia.org.pl/ (10.02.2018).
  3. Zapała J, Wyszyńska-Pawelec G. Wybrane Zagadnienia z Onkologii Głowy i Szyi. Podręcznik dla lekarzy i studentów. Wydanie I. Wydawnictwo Uniwersytetu Jagiellońskiego, Kraków 2017.
  4. Didkowska J, Wojciechowska U, Olasek P. Centrum Onkologii, Instytut im. M. Skłodowskiej-Curie. M Skłodowskiej-Curie, Warszawa 2017.
  5. Aebersold DM, Beer KT, Laissue J, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys. 2000; 48(1): 17–25.
    CrossRefPubMed
  6. Boon L, Ugarte-Berzal E, Vandooren J, et al. Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunities. Biochem J. 2016; 473(11): 1471–1482.
    CrossRefPubMed
  7. Impola U, Cuccuru MA, Masala MV, et al. Preliminary communication: matrix metalloproteinases in Kaposi's sarcoma. Br J Dermatol. 2003; 149(4): 905–907.
    CrossRefPubMed
  8. Impola U, Toriseva M, Suomela S, et al. Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer. 2003; 103(6): 709–716.
    CrossRefPubMed
  9. Murray GI. Matrix metalloproteinases: a multifunctional group of molecules. J Pathol. 2001; 195(2): 135–137, doi: 10.1002/1096-9896(200109)195:2<135::AID-PATH939>3.0.CO;2-G.
    PubMed
  10. Jayade BV, Bhat K, Patil BR, et al. Histological significance of p53 gene expression in squamous cell carcinoma of the buccal mucosa. J Maxillofac Oral Surg. 2009; 8(3): 205–210.
    CrossRefPubMed
  11. Amar S, Smith L, Fields GB. Matrix metalloproteinase collagenolysis in health and disease. Biochim Biophys Acta Mol Cell Res. 2017; 1864(11 Pt A): 1940–1951.
    CrossRefPubMed
  12. Luukkaa M, Vihinen P, Kronqvist P, et al. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck. 2006; 28(3): 225–234.
    CrossRefPubMed
  13. Mishev G, Deliverska E, Hlushchuk R, et al. Prognostic value of matrix metalloproteinases in oral squamous cell carcinoma. Biotechnol Biotechnol Equip. 2014; 28(6): 1138–1149.
    CrossRefPubMed
  14. Ranuncolo SM, Matos E, Loria D, et al. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer. 2002; 94(5): 1483–1491.
    CrossRefPubMed
  15. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990; 348(6303): 699–704.
    CrossRefPubMed
  16. Kato K, Hara A, Kuno T, et al. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. J Cancer Res Clin Oncol. 2005; 131(6): 340–346.
    CrossRefPubMed
  17. Kurahara S, Shinohara M, Ikebe T, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck. 1999; 21(7): 627–638, doi: 10.1002/(sici)1097-0347(199910)21:7<627::aid-hed7>3.0.co;2-2.
    PubMed
  18. Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol. 1999; 35(3): 227–233.
    CrossRefPubMed
  19. Yorioka CW, Coletta RD, Alves F, et al. Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int J Oncol. 2002; 20(1): 189–194.
    PubMed
  20. Rautava J, Luukkaa M, Heikinheimo K, et al. Squamous cell carcinomas arising from different types of oral epithelia differ in their tumor and patient characteristics and survival. Oral Oncol. 2007; 43(9): 911–919.
    CrossRefPubMed
  21. Tang Yi, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005; 65(8): 3193–3199.
    CrossRefPubMed
  22. Imanishi Y, Fujii M, Tokumaru Y, et al. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Hum Pathol. 2000; 31(8): 895–904.
    CrossRefPubMed
  23. Patel BP, Shah PM, Rawal UM, et al. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. J Surg Oncol. 2005; 90(2): 81–88.
    CrossRefPubMed
  24. Impola U, Jeskanen L, Ravanti L, et al. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol. 2005; 152(4): 720–726.
    CrossRefPubMed
  25. Mimori K, Yamashita K, Ohta M, et al. Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells. Clin Cancer Res. 2004; 10(24): 8243–8249.
    CrossRefPubMed
  26. American Joint Committee on Cancer: AJCC. www.cancerstaging.org (10.02.2018).
  27. Union for International Cancer Control (UICC). www.uicc.org (10.02.2018).
  28. Kapral M, Strzałka-Mrozik B, Paluch J, et al. Evaluation of gene expression of selected matrix metalloproteinases and their tissue inhibitors in laryngeal cancer. Farm Przegl Nauk. 2010; 10: 41–46.
  29. Xie M, Sun Y, Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope. 2004; 114(12): 2243–2248.
    CrossRefPubMed
  30. Zhang H, Liu M, Sun Y, et al. MMP-14 can serve as a prognostic marker in patients with supraglottic cancer. Eur Arch Otorhinolaryngol. 2009; 266(9): 1427–1434.
    CrossRefPubMed
  31. Grzelczyk WL, Wróbel-Roztropiński A, Szemraj J, et al. [The matrix metalloproteinase in oral and oropharyngeol cancer - literature review]. Postepy Biochem. 2016; 62(4): 506–510.
    PubMed
  32. Singh RD, Nilayangode H, Patel JB, et al. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer. Int J Biol Markers. 2011; 26(1): 27–36.
    CrossRefPubMed
  33. Roomi MW, Monterrey JC, Kalinovsky T, et al. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009; 21(5): 1323–1333.
    CrossRefPubMed
  34. Hong Qu, Jun T, Lei J, et al. Expression and Clinical Significance of Matrix Metalloproteinase-2 and Its Inhibitor TIMP-2 in Oral Squamous Cell Carcinoma. Journal of Hard Tissue Biology. 2006; 15(2): 54–60.
    CrossRef
  35. Kawamata H, Uchida D, Hamano H, et al. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol. 1998; 13(4): 699–704.
    PubMed
  36. Ikebe T, Shinohara M, Takeuchi H, et al. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis. 1999; 17(4): 315–323.
    CrossRefPubMed
  37. Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol. 1995; 104(9 Pt 1): 678–684.
    CrossRefPubMed
  38. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res. 2004; 10(9): 3110–3116.
    CrossRefPubMed
  39. de Vicente JC, Fresno MF, Villalain L, et al. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol. 2005; 41(3): 283–293.
    CrossRefPubMed
  40. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006; 6(3): 227–239.
    CrossRefPubMed
  41. Aebersold DM, Beer KT, Laissue J, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys. 2000; 48(1): 17–25.
    CrossRefPubMed
  42. Boon L, Ugarte-Berzal E, Vandooren J, et al. Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunities. Biochem J. 2016; 473(11): 1471–1482.
    CrossRefPubMed
  43. Impola U, Cuccuru MA, Masala MV, et al. Preliminary communication: matrix metalloproteinases in Kaposi's sarcoma. Br J Dermatol. 2003; 149(4): 905–907.
    CrossRefPubMed
  44. Impola U, Toriseva M, Suomela S, et al. Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer. 2003; 103(6): 709–716.
    CrossRefPubMed
  45. Murray GI. Matrix metalloproteinases: a multifunctional group of molecules. J Pathol. 2001; 195(2): 135–137, doi: 10.1002/1096-9896(200109)195:2<135::AID-PATH939>3.0.CO;2-G.
    PubMed
  46. Jayade BV, Bhat K, Patil BR, et al. Histological significance of p53 gene expression in squamous cell carcinoma of the buccal mucosa. J Maxillofac Oral Surg. 2009; 8(3): 205–210.
    CrossRefPubMed
  47. Amar S, Smith L, Fields GB. Matrix metalloproteinase collagenolysis in health and disease. Biochim Biophys Acta Mol Cell Res. 2017; 1864(11 Pt A): 1940–1951.
    CrossRefPubMed
  48. Luukkaa M, Vihinen P, Kronqvist P, et al. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck. 2006; 28(3): 225–234.
    CrossRefPubMed
  49. Mishev G, Deliverska E, Hlushchuk R, et al. Prognostic value of matrix metalloproteinases in oral squamous cell carcinoma. Biotechnol Biotechnol Equip. 2014; 28(6): 1138–1149.
    CrossRefPubMed
  50. Ranuncolo SM, Matos E, Loria D, et al. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer. 2002; 94(5): 1483–1491.
    CrossRefPubMed
  51. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990; 348(6303): 699–704.
    CrossRefPubMed
  52. Kato K, Hara A, Kuno T, et al. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. J Cancer Res Clin Oncol. 2005; 131(6): 340–346.
    CrossRefPubMed
  53. Kurahara S, Shinohara M, Ikebe T, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck. 1999; 21(7): 627–638, doi: 10.1002/(sici)1097-0347(199910)21:7<627::aid-hed7>3.0.co;2-2.
    PubMed
  54. Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol. 1999; 35(3): 227–233.
    CrossRefPubMed
  55. Yorioka CW, Coletta RD, Alves F, et al. Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int J Oncol. 2002; 20(1): 189–194.
    PubMed
  56. Rautava J, Luukkaa M, Heikinheimo K, et al. Squamous cell carcinomas arising from different types of oral epithelia differ in their tumor and patient characteristics and survival. Oral Oncol. 2007; 43(9): 911–919.
    CrossRefPubMed
  57. Tang Yi, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005; 65(8): 3193–3199.
    CrossRefPubMed
  58. Imanishi Y, Fujii M, Tokumaru Y, et al. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Hum Pathol. 2000; 31(8): 895–904.
    CrossRefPubMed
  59. Patel BP, Shah PM, Rawal UM, et al. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. J Surg Oncol. 2005; 90(2): 81–88.
    CrossRefPubMed
  60. Impola U, Jeskanen L, Ravanti L, et al. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol. 2005; 152(4): 720–726.
    CrossRefPubMed
  61. Mimori K, Yamashita K, Ohta M, et al. Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells. Clin Cancer Res. 2004; 10(24): 8243–8249.
    CrossRefPubMed
  62. American Joint Committee on Cancer: AJCC. www.cancerstaging.org (10.02.2018).
  63. Union for International Cancer Control (UICC). www.uicc.org (10.02.2018).
  64. Kapral M, Strzałka-Mrozik B, Paluch J, et al. Evaluation of gene expression of selected matrix metalloproteinases and their tissue inhibitors in laryngeal cancer. Farm Przegl Nauk. 2010; 10: 41–46.
  65. Xie M, Sun Y, Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope. 2004; 114(12): 2243–2248.
    CrossRefPubMed
  66. Zhang H, Liu M, Sun Y, et al. MMP-14 can serve as a prognostic marker in patients with supraglottic cancer. Eur Arch Otorhinolaryngol. 2009; 266(9): 1427–1434.
    CrossRefPubMed
  67. Grzelczyk WL, Wróbel-Roztropiński A, Szemraj J, et al. [The matrix metalloproteinase in oral and oropharyngeol cancer - literature review]. Postepy Biochem. 2016; 62(4): 506–510.
    PubMed
  68. Singh RD, Nilayangode H, Patel JB, et al. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer. Int J Biol Markers. 2011; 26(1): 27–36.
    CrossRefPubMed
  69. Roomi MW, Monterrey JC, Kalinovsky T, et al. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009; 21(5): 1323–1333.
    CrossRefPubMed
  70. Hong Qu, Jun T, Lei J, et al. Expression and Clinical Significance of Matrix Metalloproteinase-2 and Its Inhibitor TIMP-2 in Oral Squamous Cell Carcinoma. J Hard Tissue Biol. 2006; 15(2): 54–60.
    CrossRef
  71. Kawamata H, Uchida D, Hamano H, et al. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol. 1998; 13(4): 699–704.
    PubMed
  72. Ikebe T, Shinohara M, Takeuchi H, et al. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis. 1999; 17(4): 315–323.
    CrossRefPubMed
  73. Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol. 1995; 104(9 Pt 1): 678–684.
    CrossRefPubMed
  74. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res. 2004; 10(9): 3110–3116.
    CrossRefPubMed
  75. de Vicente JC, Fresno MF, Villalain L, et al. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol. 2005; 41(3): 283–293.
    CrossRefPubMed
  76. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006; 6(3): 227–239.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna